Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …

RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or
bacterial infection and induce host innate immune responses. The RLRs family comprises …

Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer
management. Nonetheless, not all patients benefit from such therapies because they fail to …

Simple Summary Beyond mutations, epigenetic changes have been described as drivers for
cancer as well. While leaving the overall DNA structure intact, they can be responsible for …

Chemotherapy is one of the most established and effective treatments for almost all types of
cancer. However, the elevated toxicity due to the non-tumor-associated effects, development …

Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 to boost tumor-
specific T lymphocyte immunity have opened up new avenues for the treatment of various …

Deregulation of protein post-translational modifications is intensively involved in the etiology
of diseases, including degenerative diseases, inflammatory injuries, and cancers …